Analysis of the world experience in countering the spread of hepatitis C among the population as a component of developing programs to increase the availability of pharmaceutical care
Keywords:hepatitis C; prevalence; hepatitis C epidemiology; government programs; non-governmental organizations; pharmaceutical care.
Aim. To analyze the world experience in countering viral hepatitis C as a component of developing programs to increase the availability of pharmaceutical care grouping countries by their level of economic development and belonging to the WHO region.
Materials and methods. The study materials were statistical reports of the WHO, national reports of countries on the prevalence, morbidity, and measures to counteract hepatitis C, as well as reports of the Polaris global study. Desk-based research methods, such as content analysis, systematic, logical, as well as methods of comparative analysis and generalization, were used.
Global Hepatitis report. 2017 / World Health Organization. URL: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
Progress report on HIV, viral hepatitis and sexually transmitted infections 2019: accountability for the global health sector strategies, 2016–2021 / World Health Organization. Geneva, 2019. URL: https://apps.who.int/iris/handle/10665/324797.
Gountas I., Sypsa V., Blach S., Razavi H. HCV elimination among people who inject drugs. Modelling pre- and post–WHO elimination era. PLoS ONE. 2018. Vol. 13, № 8. e0202109. https://doi.org/10.1371/journal.pone.0202109.
Trends in HIV, hepatitis B and hepatitis C prevalence among Australian prisoners - 2004, 2007, 2010 / J. M Reekie et al. The Medikal Jornal of Australia. 2014. Vol. 200, No. 5. P. 277-280. URL: https://onlinelibrary.wiley.com/doi/10.5694/mja13.11062.
Estimating paediatric hepatitis C prevalence in the United States / Harman Rahal et al. Jornal of Viral Hepatitis. 2020. Vol. 27, No. 12. P. 1455-1461. URL: https://onlinelibrary.wiley.com/doi/10.1111/jvh.13377.
Lanini S., Easterbrook P. J., Zumla A., Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clinical Microbiology and Infection. 2016. Vol. 22, No. 10. P. 833-838. URL: https://doi.org/10.1016/j.cmi.2016.07.035.
Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study / Q. Chen et al. J. BMJ Open. 2019. Vol. 9, No. 6. Р. e026726. DOI: 10.1136/bmjopen-2018-026726.
Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model / M. Binka et al. JAMA Netw Open. 2020. Vol. 3, No. 5. Р. e204192. DOI: 10.1001/jamanetworkopen.2020.4192.
Strategies to eliminate hepatitis C in Croatia, a modelling study / A. Vince et al. Liječnički vjesnik. 2020. Vol. 142 (9-10). Р. 285-295. URL: https://doi.org/10.26800/LV-142-9-10-44.
A micro-elimination approach to addressing hepatitis C in Turkey / R. Idilman et al. BMC Health Serv Res. 2020. Vol. 20, No. 249. URL: https://doi.org/10.1186/s12913-020-5019-8.
HCV disease burden and population segments in Switzerland / F. Bihl et al. Liver Int. 2022. Vol. 42, No. 2. Р. 330-339. DOI: 10.1111/liv.15111.
Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19 / S. Blach et al. Liver Int. 2021. Vol. 41, No. 9. Р. 2024-2031. DOI: 10.1111/liv.14978.
Kouyoumjian S. P., Chemaitelly H., Abu-Raddad L. J. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018. Vol. 8, No. 1. Р. 1661. DOI: 10.1038/s41598-017-17936-4.
Progress towards achieving viral hepatitis B and C elimination in the Asia and Pacific region: Results from modelling and global reporting / L.-V. Le et al. Liver Int. 2022. Vol. 42, No. 9. Р. 1930-1934. DOI: 10.1111/liv.15131.
Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach / A. S. Benzaken et al. Braz J Infect Dis. 2019. Vol. 23, No. 3. Р. 182-190. DOI: 10.1016/j.bjid.2019.04.010.
Spach D. H. HCV Epidemiology in the United States. URL: https://www.hepatitisc.uw.edu/go/screening-diagnosis/epidemiology-us/core-concept/all.
Nozdrina A., Volkova A., Cherkashyna A., Ovakimian O. Results of analysis of epidemological indicators of viral hepatitis c in regions of the world as part of activities to improve pharmaceutical provision for patients. ScienceRise: Pharmaceutical Science. 2022. No. 2 (36). Р. 72–80. DOI: 10.15587/2519-4852.2022.255858.
2=18 Progress report on HIV, viral hepatitis and sexually transmitted infections, 2019. Accountability for the global health sector strategies, 2016–2021. Geneva: World Health Organization; 2019. URL: https://apps.who.int/iris/handle/10665/324797.
Global health sector strategy on viral hepatitis, 2016-2021 / World Health Organization. Geneva, 2016. URL: http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1.
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study / S. Blach et al. The Lancet Gastroenterology & Hepatology. 2022. Vol. 7, No. 5. P. 396-415. DOI:10.1016/s2468-1253(21)00472-6.
Информация о ВОЗ. URL: https://www.who.int/ru/about/who-we-are.
Экономический ущерб от плохого здоровья: ситуация в Епропейском регионе. URL: https://www.euro.who.int/__data/assets/pdf_file/0009/83484/E93695R.pdf.
Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries / World Health Organization. Geneva, 2021. URL: https://www.who.int/publications/i/item/9789240019003.
The World Bank’s Classification of Countries by Income. URL: https://documents1.worldbank.org/curated/en/408581467988942234/pdf/WPS7528.pdf.
Progress towards hepatitis C virus elimination in high-income countries: An updated analysis / I. Gamkrelidze et al. Liver Int. 2021. Vol. 41, No. 3. Р. 456-463. DOI: 10.1111/liv.14779.
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy / F. Ansaldi et al. World J Gastroenterol. 2014. Vol. 20, No. 29. Р. 9633-52. DOI: 10.3748/wjg.v20.i29.9633.
Copyright (c) 2022 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).